LIQUIDIA CORPORATION -

Liquidia Corporation to Report Second Quarter 2023 Financial Results on August 10, 2023

03 Aug 2023 07:17:48 By Nasdaq GlobeNewswire

Liquidia Submits Amendment to Add PH-ILD Indication to Tentatively Approved NDA for YUTREPIA™ (treprostinil) Inhalation Powder

27 Jul 2023 05:00:23 By Nasdaq GlobeNewswire

Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Sustained-Release Inhaled Treprostinil Product in North America

28 Jun 2023 04:36:17 By Nasdaq GlobeNewswire

Liquidia Corporation to Present at the 2023 Jefferies Healthcare Conference

31 May 2023 05:30:39 By Nasdaq GlobeNewswire

Liquidia Announces Poster Presentation at the 2023 American Thoracic Society International Conference

19 May 2023 05:15:10 By Nasdaq GlobeNewswire

Liquidia Corporation Reports First Quarter 2023 Financial Results and Provides Corporate Update

04 May 2023 05:30:29 By Nasdaq GlobeNewswire

Liquidia Corporation to Present at BofA Securities 2023 Health Care Conference

02 May 2023 05:45:49 By Nasdaq GlobeNewswire

Liquidia Corporation to Report First Quarter 2023 Financial Results on May 4, 2023

27 Apr 2023 05:45:59 By Nasdaq GlobeNewswire

Liquidia Corporation to Present at 22nd Annual Needham Virtual Healthcare Conference

11 Apr 2023 05:45:01 By Nasdaq GlobeNewswire

Liquidia and GSK Restructure License to PRINT Technology for Inhaled Applications

03 Apr 2023 05:45:19 By Nasdaq GlobeNewswire

Liquidia Corporation Reports Full Year 2022 Financial Results and Provides Corporate Update

16 Mar 2023 05:30:33 By Nasdaq GlobeNewswire

Liquidia Corporation to Report Full Year 2022 Financial Results on Thursday, March 16, 2023

09 Mar 2023 06:19:38 By Nasdaq GlobeNewswire

Patent Trial and Appeal Board (PTAB) Reaffirms Decision to Invalidate All Claims of United Therapeutics (UTHR) Patent No. 10,716,793 (‘793 Patent)

02 Feb 2023 15:39:33 By Nasdaq GlobeNewswire

Liquidia Corporation Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

02 Feb 2023 05:30:10 By Nasdaq GlobeNewswire

Liquidia Enters Into a Revenue Interest Financing Agreement With HealthCare Royalty for Up to $100 Million

09 Jan 2023 05:30:00 By Nasdaq GlobeNewswire

Liquidia Announces Collaboration to Develop a New Infusion Pump for Subcutaneous Delivery of Treprostinil Injection to Treat Pulmonary Arterial Hypertension (PAH)

05 Dec 2022 15:05:39 By Nasdaq GlobeNewswire

Liquidia Reports Third Quarter 2022 Financial Results and Provides Corporate Update

08 Nov 2022 05:30:10 By Nasdaq GlobeNewswire

Liquidia to Report Third Quarter 2022 Financial Results on November 8, 2022

01 Nov 2022 05:45:16 By Nasdaq GlobeNewswire

Precedential Opinion Panel Denies United Therapeutics’ Request for Review of ‘793 Inter Partes Review Decision

27 Oct 2022 15:10:00 By Nasdaq GlobeNewswire

Liquidia Announces Presentations at the CHEST 2022 Annual Meeting

17 Oct 2022 05:30:00 By Nasdaq GlobeNewswire